APG has identified a new way of preventing aggregation, oligomer formation and seeding of mutated huntingtin. The drug candidate is a small molecule, which may be applied orally. Clinically modifying the function of the identified drug target has the potential to modulate HD pathology, improve symptoms, and slow down cognitive decline, behavioral changes and movement abnormalities.
We are currently testing analogs of our hits with a binding assay to identify small molecules with improved affinity to the drug target. We have so far early leads with excellent in vitro blood brain barrier penetrability and high solubility.
Avergen is pursuing collaboration with university researchers and other pharmaceutical companies. Working with external partners allows Avergen to access different pools of knowledge and save R&D costs. Thus guaranteeing successful innovation. Partnerships will be maintained throughout the whole life cycle of our development programme and products.
In 2016 we have started a research collaboration with the University of California, Irvine.